Our Pricing

What to Expect From Mounjaro in Your First Month

Published on: June 03, 2026

Searching for mounjaro before and after 1 month UK results? At Cured Pharmacy, our UK prescribers help patients understand realistic expectations: clinical trials show average weight loss of 2-4kg during the initial four weeks on the 2.5mg starter dose, with progressive increases as dosage escalates [1]. We provide genuine UK-licensed Mounjaro from £124.99 with transparent pricing and free clinical consultation.

Mounjaro Before and After 1 Month: Clinical Evidence

During the first month of Mounjaro treatment, patients typically remain on the 2.5mg starter dose for four weeks as part of the MHRA-approved titration schedule [1]. Clinical trial data from the SURPASS programme demonstrates that this initial period focuses on tolerability rather than maximum weight loss, with participants experiencing an average reduction of 2-4kg (approximately 2-4% of baseline body weight) during weeks 0-4 [2].

The modest first-month results reflect tirzepatide's gradual mechanism of action. As a dual GIP/GLP-1 receptor agonist, Mounjaro requires time to regulate appetite hormones, slow gastric emptying, and improve insulin sensitivity [1]. Patients who continue treatment beyond one month typically see accelerated weight loss as doses increase to 5mg, 7.5mg, 10mg, 12.5mg, and ultimately 15mg over subsequent months, subject to prescriber approval and tolerability.

It's essential to set realistic expectations: dramatic transformations within 30 days are uncommon. The SURPASS-1 trial recorded mean weight reductions of 1.9kg at week 4 on the 5mg dose, rising to 7.0kg by week 20 and 15.0kg by week 40 [2]. Your UK prescriber will monitor progress throughout the titration period to optimise outcomes whilst minimising gastrointestinal side effects.

How Mounjaro Works in the First Four Weeks

Tirzepatide, the active ingredient in Mounjaro, activates both glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously [3]. This dual-action mechanism distinguishes it from semaglutide-based treatments like Wegovy, which target GLP-1 receptors alone. During your first month, these pathways begin reducing appetite signals, slowing food transit through the stomach, and improving your body's insulin response to meals.

Most patients notice appetite suppression within the first 1-2 weeks, often reporting earlier satiety and reduced cravings for high-calorie foods [1]. However, the full metabolic benefits take longer to manifest. Gastric emptying slows progressively, and insulin sensitivity improvements accumulate over weeks rather than days. This is why the initial 2.5mg dose serves primarily as a tolerability step rather than a therapeutic endpoint.

The starter dose also allows your body to adapt to common side effects. Nausea, mild diarrhoea, and reduced appetite are most pronounced during dose escalations [3]. By introducing tirzepatide gradually, the MHRA-approved titration schedule minimises discontinuation rates whilst building toward the higher doses (10mg, 12.5mg, 15mg) where clinical trials recorded average weight reductions exceeding 20% over 72 weeks [2].

Managing First-Month Side Effects

Gastrointestinal symptoms affect approximately 20-30% of patients during the first month, typically mild to moderate in severity [3]. Our UK clinical team recommends smaller, more frequent meals, avoiding high-fat foods, and staying well-hydrated to minimise nausea. Most side effects diminish within 2-3 weeks as your body adjusts to the medication. If symptoms persist or worsen, your prescriber may extend the 2.5mg phase before escalating to 5mg.

Mounjaro vs Wegovy: First Month Comparison

Patients often compare Mounjaro before and after 1 month UK results with Wegovy (semaglutide) outcomes during the same timeframe. Both medications follow gradual titration schedules, but their mechanisms differ significantly. Wegovy's single-pathway GLP-1 action produces average first-month weight loss of 1.5-3kg on the 0.25mg starter dose, slightly lower than Mounjaro's dual-receptor approach [4].

The STEP 1 trial, which evaluated semaglutide for weight management, showed mean weight reductions of 2.3kg at week 4, compared to 2.9kg in SURPASS-1 participants on tirzepatide 5mg [2][4]. However, direct comparisons require caution: trial populations, baseline BMI ranges, and dietary interventions varied between studies. Both medications require prescription assessment by a UK prescriber and demonstrate superior efficacy when combined with lifestyle modifications.

From a practical standpoint, Mounjaro's once-weekly KwikPen administration matches Wegovy's dosing frequency, making convenience comparable. The choice between treatments depends on individual medical history, tolerability, and cost considerations. At Cured Pharmacy, Mounjaro starts from £124.99 and Wegovy from £124.99, with final pricing determined by your prescribed dose following clinical consultation.

Which Treatment Suits Your Goals?

Your UK prescriber will assess factors including BMI, previous weight loss attempts, cardiovascular risk factors, and budget to recommend the most appropriate option. Patients with higher baseline BMI (≥35 kg/m²) may benefit from Mounjaro's dual-receptor mechanism, whilst those seeking lower upfront costs might start with Wegovy, subject to clinical suitability and stock availability.

Realistic Mounjaro 1 Month Results Timeline

Week 1-2: Most patients report reduced appetite and early satiety, with minimal weight change (typically 0.5-1kg). The 2.5mg starter dose begins modulating hunger hormones, though metabolic effects remain limited [1]. Mild nausea may occur, usually resolving within days. Focus during this period centres on establishing your injection routine and adjusting meal sizes.

Week 3-4: Weight loss accelerates slightly as gastric emptying slows and calorie intake decreases. By day 28, average reductions reach 2-4kg, though individual variation is substantial [2]. Some patients lose 5-6kg if they implement significant dietary changes, whilst others see 1-2kg reductions. Your prescriber will review progress at the four-week mark to determine readiness for dose escalation to 5mg.

Beyond Month 1: The most significant weight loss occurs between months 2-6 as doses increase toward maintenance levels (10mg, 12.5mg, or 15mg). SURPASS trial participants on 15mg tirzepatide achieved average reductions of 9.5kg by week 20 and 22.5% total body weight by week 72 [2]. Patience during the initial titration period is essential for long-term success and tolerability.

Maximising Your First Month on Mounjaro

Clinical outcomes improve significantly when Mounjaro is combined with structured lifestyle interventions. The SURPASS trials mandated a 500-calorie daily deficit and at least 150 minutes of moderate exercise weekly [2]. Patients who adhere to these guidelines consistently outperform those relying on medication alone, with first-month weight loss averaging 3-4kg versus 1.5-2kg in less adherent groups.

Practical strategies include meal planning to accommodate reduced appetite, prioritising protein intake to preserve lean muscle mass, and tracking physical activity. Many patients find that Mounjaro's appetite-suppressing effects make calorie restriction easier to sustain compared to diet-only approaches. However, adequate nutrition remains critical—severely restrictive eating can trigger fatigue, hair thinning, and muscle loss over time.

Hydration deserves particular attention during the first month. Reduced food intake and potential gastrointestinal side effects increase dehydration risk, which can worsen nausea and constipation [3]. Aim for 2-3 litres of water daily, adjusting for activity level and climate. Your UK prescriber can provide personalised guidance during your follow-up consultations to optimise both safety and efficacy.

Monitoring Progress Beyond the Scale

Weight fluctuates daily due to hydration, sodium intake, and hormonal cycles. Rather than obsessing over day-to-day changes, focus on weekly averages and non-scale victories: improved energy levels, better-fitting clothes, reduced joint pain, and enhanced mobility. These indicators often manifest before substantial weight loss becomes visible, particularly during the first month when changes remain modest.

Getting Started with Mounjaro at Cured Pharmacy

All Mounjaro prescriptions at Cured Pharmacy begin with a free online consultation completed in under three minutes. Our UK-registered prescribers (overseen by Superintendent Pharmacist Tarun Kumar, GPhC 2233073) review your medical history, current medications, weight loss goals, and any contraindications to ensure tirzepatide is clinically appropriate. Approval is subject to meeting MHRA licensing criteria, typically BMI ≥30 kg/m² or ≥27 kg/m² with weight-related comorbidities.

Once approved, your Mounjaro KwikPen is dispensed from our GPhC-registered pharmacy (9012511) and delivered in 100% discreet packaging. Pricing starts from £124.99 for the 2.5mg starter dose, with transparent costs displayed before consultation—no hidden fees or surprise charges. We guarantee the lowest prices in the UK on genuine, UK-licensed medications sourced directly from licensed wholesalers.

Follow-up consultations occur at four-week intervals to monitor progress, assess tolerability, and adjust dosing as needed. Your prescriber will guide you through the titration schedule, typically escalating to 5mg at week 5, 7.5mg at week 9, and so forth until reaching your optimal maintenance dose. This structured approach maximises long-term success whilst minimising side effects, ensuring your Mounjaro journey extends well beyond the first month.

Why Choose Cured Pharmacy for Weight Loss Treatment

Cured Pharmacy combines clinical expertise, regulatory compliance, and patient-centred care. Our UK prescribers have supported thousands of weight loss journeys, providing evidence-based guidance rather than generic advice. With transparent upfront pricing, discreet delivery, and ongoing clinical support, we make accessing prescription weight loss treatments straightforward and affordable. Start your free consultation today to explore whether Mounjaro is right for you.

Scientific References

1. Electronic Medicines Compendium. (2023). Mounjaro 2.5 mg solution for injection in pre-filled pen - Summary of Product Characteristics. https://www.medicines.org.uk/emc/product/14441 [accessed 13 August 2026]
2. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
3. Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021). GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art. Molecular Metabolism, 46, 101102. https://doi.org/10.1016/j.molmet.2020.101102 [accessed 13 August 2026]
4. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
5. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
6. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
7. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary. Weight loss outcomes depend on adherence to prescribed treatment, dietary modifications, and physical activity levels.